Accelerating Therapeutic Discovery: ATX-Gx™ Human, Transgenic Platform
Webinar Overview Ready to dramatically accelerate your therapeutic antibody discovery pipeline? In this presentation, Dr. John “Lippy” Lippincott shares how our ATX-Gx™ human, transgenic mouse platform can help: Accelerate antibody discovery: Learn how this platform, used by 100’s of biotechs and large pharma, can significantly speed up the identification of therapeutic antibody candidates against diverse […]
High Velocity AI-Enabled and ML-Powered Therapeutic Antibody Discovery
High velocity, AI-enabled and ML-powered therapeutic antibody discovery and optimization Download the poster to see how Al/ML technologies and workflows combined with a proprietary high-throughput screening method accelerate antibody discovery and lead optimization. Download the poster Contact Us AI-enabled and ML-powered antibody discovery for faster and higher quality leads Therapeutic antibody discovery is becoming faster […]
Highly Specific anti-WT1/HLA-A2 TCRm Antibodies
New Data: unlocking the potential of TCRm antibodies Download the poster and explore the discovery of highly specific anti-WT1/HLA-A2 TCR-like antibodies. Download the poster Contact Us Keyway™ TCRm antibody discovery platform is revolutionizing immunotherapy development In a significant study, Alloy Therapeutics researchers identified T Cell Receptor mimic (TCRm) antibodies with exceptional specificity for the Wilms […]
How AI is reshaping antibody discovery and optimization workflows
In silico antibody discovery and optimization: How computational tools are reshaping the workflow AI-enabled and ML-powered methods are enabling faster identification and engineering of high-quality therapeutic antibody leads The field of antibody discovery is experiencing a transformative shift through the integration of cutting-edge artificial intelligence (AI) and machine learning (ML) technologies. Traditional methods of antibody […]
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform
Collaboration builds on Alloy’s existing and highly productive engagement with Pfizer and will apply Alloy’s innovation expertise to address Pfizer’s specific antibody discovery objectives
Alloy Therapeutics Announces New Licensing Model for ATX-Gx™ Antibody Discovery Platform and Launches mAbForge™ High-Throughput Screening Service
Boston, MA, January 9th, 2025 – Alloy Therapeutics (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today that it is launching a new market-disrupting licensing structure. Partners can now have the option to use the ATX-GxTM antibody technology platform with no annual access fee or development milestones. […]
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
Boston, MA, January 7th, 2025 – Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target specific collaboration and license agreement for the use of their novel and proprietary AntiClastic Antisense Platform with Sanofi for a central nervous system (CNS) target. In return, […]
Discovering Antibodies in Months
Access the webinar recording Thanks for your interest in our recent antibody discovery webinar, Discovering Antibodies in Months: New Advances in HT-SPR, Single-Cell BCR-Seq and RNA-Seq. Alloy Head of Global Bioanalytics Dr. Lucy Liu presented on our workflow that improve the speed and quality of the antibody discovery process. Please fill out your contact information, and […]
Approaches to Binder Recovery Following Immunization Campaigns in Mouse Models
Harnessing the Potential of Human Lambda Light Chains in Antibody Discovery Campaigns
